GlassScriptPhysician profile
David M Lans
NPI 1720086051
$15,311.91
in general payments reported to CMS, 2019-2025
44 companies · $2,814 in 2025
The $2,814 reported for 2025 was more than what 76% of Rheumatology providers received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,848 · 2020: $1,741 · 2021: $2,246 · 2022: $2,101 · 2023: $1,879 · 2024: $2,683 · 2025: $2,814.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,127 · Education: $249.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,126.83 |
| Education | $248.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $2,496.54 | 2019-2025 | Evenity, Prolia, Otezla |
| Astrazeneca Pharmaceuticals LP | $2,369.21 | 2019-2025 | Saphnelo, Breztri, Fasenra |
| Abbvie INC. | $2,118.13 | 2019-2025 | |
| Janssen Biotech, INC. | $1,196.15 | 2019-2025 | Tremfya, Simponi Aria, Remicade |
| Pfizer INC. | $978.94 | 2019-2025 | |
| Ucb, INC. | $807.62 | 2019-2025 | Bimzelx, Cimzia |
| Novartis Pharmaceuticals Corporation | $662.62 | 2019-2025 | Leqvio |
| Mallinckrodt Hospital Products INC. | $601.44 | 2020-2025 | Acthar |
| Lilly USA, LLC | $583.66 | 2019-2024 | Taltz, Zepbound, Jardiance |
| Glaxosmithkline, LLC. | $366.33 | 2019-2025 | Benlysta |
| Antares Pharma, INC. | $327.02 | 2019-2025 | Xyosted |
| E.R. Squibb & Sons, L.L.C. | $291.98 | 2019-2025 | Orencia |
| Organon LLC | $248.57 | 2021-2025 | Renflexis, Hadlima |
| Ani Pharmaceuticals, INC. | $241.76 | 2022-2025 | Purified Cortrophin Gel |
| Genentech, INC. | $191.80 | 2020 |
Show all 44 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Lans listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.